Bayesian Trial Submissions Could Consume More FDA Resources, CDRH Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Device center statisticians currently spend at most 5%-10% of their time and effort evaluating Bayesian statistical analyses in premarket submissions, but the center continues to ramp up its resources to deal with a potential influx relying on the advanced technique.
You may also be interested in...
Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term
The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.
Feds Try To Pave Path For Frustrated Pediatric Device Innovators
NIH and government agencies plan to submit plans to Congress next month describing ways to encourage the development of medical devices for children.
Legal Issues Abound For Device Marketers In The Blogosphere
Do not be cavalier about this venue, drug/device lawyer warns.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: